CClinicalTrials.gg
Not yet recruitingNCT07797946Updated Sep 1, 2026

Preoperative Ivabradine Doses for Hemodynamic Stability in FESS

An interventional study of Ivabradine 5 mg/5 mg regimen and Ivabradine 5 mg/7.5 mg regimen in Hemodynamic Instability, sponsored by Minia University. Not yet recruiting. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Minia University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

This study compares two different preoperative doses of a heart-rate-lowering medication called ivabradine in patients undergoing endoscopic sinus surgery under general anesthesia. Patients will receive either a lower dose, a higher dose, or a placebo (inactive pill) before surgery. The goal is to see which approach best keeps blood pressure and heart rate stable during surgery, and whether it reduces bleeding and improves the surge

Read the detailed description

This is a prospective, randomized, double-blind, placebo-controlled, parallel-group trial conducted at Minia University Hospital. Eighty-four patients aged 21-60 years, ASA physical status I or II, scheduled for functional endoscopic sinus surgery (FESS) under general anesthesia, with a baseline heart rate of 70 beats per minute or higher in sinus rhythm, will be randomly allocated into three equal groups. Group A will receive ivabradine 5 mg the night before surgery plus 5 mg on the morning of surgery; Group B will receive ivabradine 5 mg the night before plus 7.5 mg on the morning of surgery; Group C will receive a placebo (folic acid) on both occasions. Randomization codes will be concealed in sequentially numbered opaque sealed envelopes, and study medication will be prepared by an independent pharmacist to maintain blinding. Hemodynamic parameters will be recorded at standardized time points throughout the perioperative period. Surgical field visibility will be assessed using the Boezaart Bleeding Scale, and recovery will be assessed using the modified Aldrete Score. The study aims to determine which ivabradine regimen provides superior hemodynamic stability and surgical field conditions during FESS.

02

Conditions studied

  • Hemodynamic Instability

Keywords

  • Ivabradine • Functional Endoscopic Sinus Surgery • Controlled Hypotension • Heart Rate
03

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 21 and 60 years of both sexes
  • ASA physical status I or II
  • Baseline heart rate ≥ 70 beats per minute in sinus rhythm on preoperative ECG

Exclusion criteria

Exclusion Criteria:

  • Patient refusal or inability to provide informed consent
  • Baseline heart rate \<70 beats per minute or any degree of heart block on preoperative ECG
  • Current use of beta blockers, calcium channel blockers, digoxin, or any antiarrhythmic agent
  • Severe hepatic impairment (Child-Pugh class C) or renal impairment (eGFR\<30 ml/min)
  • Pregnancy or breastfeeding
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A: Ivabradine 5 mg/5 mg

    Patients received oral ivabradine 5 mg the night before surgery and an additional 5 mg on the morning of surgery.

    Drug: Ivabradine 5 mg/5 mg regimen

  • Experimental
    Group B: Ivabradine 5 mg/7.5 mg

    Patients received oral ivabradine 5 mg the night before surgery and an additional 7.5 mg on the morning of surgery.

    Drug: Ivabradine 5 mg/7.5 mg regimen

  • Placebo comparator
    Placebo

    Patients received an oral placebo (folic acid) the night before surgery and on the morning of surgery, following the same schedule as the treatment groups.

    Drug: Placebo

Interventions

  • DrugIvabradine 5 mg/5 mg regimen

    Oral ivabradine 5 mg administered the night before surgery, followed by an additional 5 mg on the morning of surgery.

  • DrugIvabradine 5 mg/7.5 mg regimen

    Oral ivabradine 5 mg administered the night before surgery, followed by an additional 7.5 mg on the morning of surgery.

  • DrugPlacebo

    Oral placebo (folic acid) administered the night before surgery and on the morning of surgery, following the same schedule as the treatment groups.

05

What researchers measure

Primary outcomes

  1. Intraoperative Heart Rate Stability

    Comparison of heart rate (beats per minute) at standardized intraoperative time points (T0-T10) across the three ivabradine dosing groups, to assess hemodynamic stability during FESS under general anesthesia.

    Time frame: Intraoperative, from induction of anesthesia through end of surgery (approximately 60-90 minutes)

  2. Intraoperative Mean Arterial Pressure Stability

    Comparison of mean arterial pressure (mmHg) at standardized intraoperative time points (T0-T10) across the three ivabradine dosing groups, to assess hemodynamic stability during FESS under general anesthesia.

    Time frame: Intraoperative, from induction of anesthesia through end of surgery (approximately 60-90 minutes)

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07797946
Lead sponsor
Minia University
Responsible party
Yahia Magdi Mohamed Ali (Physician, Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Minia University, Minia University) — Principal investigator
First posted
Sep 1, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

yahia Magdi Mohamed, Resident in Anesthesia
Contact
magdiyahia6@gmail.com
0201112072006

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion